Puma Biotechnology raises $10M via private placement with CEO and Athyrium

PUMA BIOTECHNOLOGY, INC.

Sold 3,584,228 shares at $2.79 each to CEO Alan Auerbach and an Athyrium fund for $10M gross proceeds.
Each purchaser committed ~$5M; placement closed March 10, 2022, at closing price.
Proceeds will be used for general corporate purposes; company to file resale registration statement within 135 days.
Private placement exempt from registration under Section 4(a)(2) of Securities Act.
CEO Auerbach participated alongside Athyrium, an existing noteholder affiliate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.